This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
by Kinjel Shah
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy
by Zacks Equity Research
Allogene Therapeutics (ALLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research
by Zacks Equity Research
Regeneron is set to acquire 23andMe assets for $256 million to boost genetic drug discovery. The transaction is expected to close by third-quarter 2025.
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
by Zacks Equity Research
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
by Zacks Equity Research
Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
by Zacks Equity Research
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
by Zacks Equity Research
Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
by Zacks Equity Research
The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate.
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
by Zacks Equity Research
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adherex Technologies (FENC) delivered earnings and revenue surprises of -110.71% and 73.17%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -4.35% and 2.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases
by Zacks Equity Research
The FDA clears ALLO's investigational new drug application to start clinical studies on its investigational CAR T product, ALLO-329, for autoimmune diseases.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
by Sundeep Ganoria
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
by Sundeep Ganoria
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.
PCRX Receives New Patent for Lead Pain Drug Exparel in the US
by Zacks Equity Research
The U.S. Patent and Trademark Office grants a new patent to protect the chemical composition of Pacira's lead pain-management drug, Exparel.
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
by Zacks Equity Research
Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?
by Sundeep Ganoria
The dip in ALLO's share price can be attributed to strategic changes in its pipeline, which delayed bringing its lead drug to market by at least two years.
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
by Zacks Equity Research
Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.
APLT Stock Plunges 77% After FDA Issues CRL for Galactosemia Drug NDA
by Zacks Equity Research
Applied Therapeutics stock plummets 77% after the FDA issues a CRL for the company's NDA seeking approval for govorestat to treat classic galactosemia.